MedTrace Logo

P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI

NCT01967615 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4500

Last updated 2017-10-30

No results posted yet for this study

Summary

Prasugrel and ticagrelor were both associated with a significant reduction in the risk of MACE in patients undergoing PCI for an ACS, mostly through a reduced stent thrombosis. The 1-year relative risk reduction (RRR) of definite of probable stent thrombosis in patients receiving a DES were fairly different in TRITON-TIMI 38 and PLATO trials. The incidence of "biologically active" stent (DES or BVS) thrombosis is largely variable according to different lesion settings. We aim to verify the translation of the postulated different reduction in thrombosis rate among various P2Y12 inhibitors (clopidogrel, prasugrel and ticagrelor) in a high-risk setting such as the PCI with DES or BVS in CTO and bifurcating lesions.

Conditions

  • Coronary Arteriosclerosis

Sponsors & Collaborators

  • G. d'Annunzio University

    lead OTHER

Principal Investigators

  • Marco Zimarino, MD · G. d'Annunzio University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-05-31
Completion
2017-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01967615 on ClinicalTrials.gov